208 related articles for article (PubMed ID: 24471998)
1. Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development.
Slusarczyk M; Lopez MH; Balzarini J; Mason M; Jiang WG; Blagden S; Thompson E; Ghazaly E; McGuigan C
J Med Chem; 2014 Feb; 57(4):1531-42. PubMed ID: 24471998
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological activity of a gemcitabine phosphoramidate prodrug.
Wu W; Sigmond J; Peters GJ; Borch RF
J Med Chem; 2007 Jul; 50(15):3743-6. PubMed ID: 17602464
[TBL] [Abstract][Full Text] [Related]
3. NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials.
Kapacee ZA; Knox JJ; Palmer D; Blagden SP; Lamarca A; Valle JW; McNamara MG
Med Oncol; 2020 Jun; 37(7):61. PubMed ID: 32529264
[TBL] [Abstract][Full Text] [Related]
4. Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031.
Sarr A; Bré J; Um IH; Chan TH; Mullen P; Harrison DJ; Reynolds PA
Sci Rep; 2019 May; 9(1):7643. PubMed ID: 31113993
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer.
Arora M; Bogenberger JM; Abdelrahman A; Leiting JL; Chen X; Egan JB; Kasimsetty A; Lenkiewicz E; Malasi S; Uson PLS; Nagalo BM; Zhou Y; Salomao MA; Kosiorek HE; Braggio E; Barrett MT; Truty MJ; Borad MJ
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1063-1078. PubMed ID: 32440762
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.
Samulitis BK; Pond KW; Pond E; Cress AE; Patel H; Wisner L; Patel C; Dorr RT; Landowski TH
Cancer Biol Ther; 2015; 16(1):43-51. PubMed ID: 25485960
[TBL] [Abstract][Full Text] [Related]
8. Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors.
Minami K; Shinsato Y; Yamamoto M; Takahashi H; Zhang S; Nishizawa Y; Tabata S; Ikeda R; Kawahara K; Tsujikawa K; Chijiiwa K; Yamada K; Akiyama S; Pérez-Torras S; Pastor-Anglada M; Furukawa T; Yasuo T
J Pharmacol Sci; 2015 Mar; 127(3):319-25. PubMed ID: 25837929
[TBL] [Abstract][Full Text] [Related]
9. Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd).
Nishio R; Tsuchiya H; Yasui T; Matsuura S; Kanki K; Kurimasa A; Hisatome I; Shiota G
Cancer Sci; 2011 Mar; 102(3):622-9. PubMed ID: 21205085
[TBL] [Abstract][Full Text] [Related]
10. Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance.
Dalin S; Sullivan MR; Lau AN; Grauman-Boss B; Mueller HS; Kreidl E; Fenoglio S; Luengo A; Lees JA; Vander Heiden MG; Lauffenburger DA; Hemann MT
Cancer Res; 2019 Nov; 79(22):5723-5733. PubMed ID: 31484670
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study.
Blagden SP; Rizzuto I; Suppiah P; O'Shea D; Patel M; Spiers L; Sukumaran A; Bharwani N; Rockall A; Gabra H; El-Bahrawy M; Wasan H; Leonard R; Habib N; Ghazaly E
Br J Cancer; 2018 Oct; 119(7):815-822. PubMed ID: 30206366
[TBL] [Abstract][Full Text] [Related]
12. Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine.
Vande Voorde J; Sabuncuoğlu S; Noppen S; Hofer A; Ranjbarian F; Fieuws S; Balzarini J; Liekens S
J Biol Chem; 2014 May; 289(19):13054-65. PubMed ID: 24668817
[TBL] [Abstract][Full Text] [Related]
13. Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase.
Weizman N; Krelin Y; Shabtay-Orbach A; Amit M; Binenbaum Y; Wong RJ; Gil Z
Oncogene; 2014 Jul; 33(29):3812-9. PubMed ID: 23995783
[TBL] [Abstract][Full Text] [Related]
14. Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression.
Wonganan P; Lansakara-P DS; Zhu S; Holzer M; Sandoval MA; Warthaka M; Cui Z
J Control Release; 2013 Jul; 169(1-2):17-27. PubMed ID: 23570983
[TBL] [Abstract][Full Text] [Related]
15. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
[TBL] [Abstract][Full Text] [Related]
16. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells.
Saiki Y; Yoshino Y; Fujimura H; Manabe T; Kudo Y; Shimada M; Mano N; Nakano T; Lee Y; Shimizu S; Oba S; Fujiwara S; Shimizu H; Chen N; Nezhad ZK; Jin G; Fukushige S; Sunamura M; Ishida M; Motoi F; Egawa S; Unno M; Horii A
Biochem Biophys Res Commun; 2012 Apr; 421(1):98-104. PubMed ID: 22490663
[TBL] [Abstract][Full Text] [Related]
17. Single Diastereomers of the Clinical Anticancer ProTide Agents NUC-1031 and NUC-3373 Preferentially Target Cancer Stem Cells
Slusarczyk M; Serpi M; Ghazaly E; Kariuki BM; McGuigan C; Pepper C
J Med Chem; 2021 Jun; 64(12):8179-8193. PubMed ID: 34085825
[TBL] [Abstract][Full Text] [Related]
18. A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms.
Alexander RL; Greene BT; Torti SV; Kucera GL
Cancer Chemother Pharmacol; 2005 Jul; 56(1):15-21. PubMed ID: 15789226
[TBL] [Abstract][Full Text] [Related]
19. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
Rajabpour A; Afgar A; Mahmoodzadeh H; Radfar JE; Rajaei F; Teimoori-Toolabi L
Cancer Chemother Pharmacol; 2017 Oct; 80(4):765-775. PubMed ID: 28887583
[TBL] [Abstract][Full Text] [Related]
20. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
Ruiz van Haperen VW; Veerman G; Eriksson S; Stegmann AP; Peters GJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):35-41. PubMed ID: 7481843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
